News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Cambridge Heart’s Alternans Test Gains Additional Reimbursement Acceptance; CareFirst Blue Cross/Blue Shield Issues Medical Policy For MTWA Testing
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Cambridge Heart, Inc. (OTCBB: CAMH) today announced that CareFirst Blue Cross/Blue Shield has issued a medical policy providing coverage of its Microvolt T-Wave Alternans (MTWA) Test.
Twitter
LinkedIn
Facebook
Email
Print